Provided by Tiger Trade Technology Pte. Ltd.

Tonix Pharmaceuticals

13.74
+0.15001.10%
Volume:152.42K
Turnover:2.09M
Market Cap:235.65M
PE:-1.10
High:14.04
Open:13.68
Low:13.35
Close:13.59
52wk High:31.55
52wk Low:9.40
Shares:17.15M
Float Shares:14.99M
Volume Ratio:0.59
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.4882
EPS(LYR):-14.5713
ROE:-81.82%
ROA:-46.84%
PB:1.06
PE(LYR):-0.94

Loading ...

Tonix CEO Seth Lederman Acquires 2,000 Common Shares for $27,580

Reuters
·
Yesterday

Tonix Pharma Director Richard H. Bagger Acquires Common Shares Worth $12,600

Reuters
·
Aug 24

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 24

Tonix Names CEO Seth Lederman Interim Chief Medical Officer

Reuters
·
Aug 19

Tonix Pharmaceuticals: Stronger-Than-Expected Tonmya Launch, Expanded Market Access, and Advancing Pipeline Underpin Buy Rating

TIPRANKS
·
Aug 11

Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James

TIPRANKS
·
Aug 11

Tonix Pharmaceuticals Holding Corp. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Tonix Pharmaceuticals reports Q2 EPS ($2.44), consensus ($2.62)

TIPRANKS
·
Aug 10

Tonix Q2 Revenue Rises Sharply on Tonmya Launch

Reuters
·
Aug 10

Tonix Q2 FY26 Net Loss Narrows to $40.55 Million; Product Revenue Rises to $13.54 Million

Reuters
·
Aug 10

Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate

Benzinga Earnings
·
Aug 10

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

THOMSON REUTERS
·
Aug 10

Tonix Pharmaceuticals Q2 Net Income USD -40.552 Million

THOMSON REUTERS
·
Aug 10

Tonix Pharmaceuticals Holding Corp. Expected to Post a Loss of $2.70 a Share - Earnings Preview

Reuters
·
Aug 08

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Aug 05

Tonix Publishes Investor Deck Highlighting Tonmya Fibromyalgia Launch and Pipeline Updates

Reuters
·
Aug 04

Tonix Pharmaceuticals receives Type C meeting minutes from FDA for TNX-4800

TIPRANKS
·
Aug 03

Tonix Plans Adaptive Phase 2 Trial of TNX-4800 Antibody to Prevent Lyme Disease, Targets Q1 2027 Start

Reuters
·
Aug 03

Tonix Pharmaceuticals - Plans to Start Phase 2 Tnx-4800 Study in Q1 2027

THOMSON REUTERS
·
Aug 03

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of Tnx-4800, a Human, Anti-Ospa Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

THOMSON REUTERS
·
Aug 03